MDGL - Madrigal Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.47B
Enterprise Value 3986.59M
Trailing P/E N/A
Forward P/E 1-13.70
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)3.13
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-19.11

Trading Information

Stock Price History

Beta (3Y Monthly) 1.65
52-Week Change 3-67.12%
S&P500 52-Week Change 36.42%
52 Week High 3292.29
52 Week Low 389.83
50-Day Moving Average 399.61
200-Day Moving Average 3114.30

Share Statistics

Avg Vol (3 month) 3162.51k
Avg Vol (10 day) 3118.95k
Shares Outstanding 514.25M
Float 6.41M
% Held by Insiders 111.33%
% Held by Institutions 197.08%
Shares Short (Jun 28, 2019) 42.48M
Short Ratio (Jun 28, 2019) 413.16
Short % of Float (Jun 28, 2019) 436.49%
Short % of Shares Outstanding (Jun 28, 2019) 416.06%
Shares Short (prior month May 31, 2019) 42.09M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 235/1
Last Split Date 3Jul 25, 2016

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-9.75%
Return on Equity (ttm)-12.86%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -51.63M
Net Income Avi to Common (ttm)-41.53M
Diluted EPS (ttm)-2.75
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)477.82M
Total Cash Per Share (mrq)30.99
Total Debt (mrq)900k
Total Debt/Equity (mrq)0.19
Current Ratio (mrq)45.75
Book Value Per Share (mrq)30.39

Cash Flow Statement

Operating Cash Flow (ttm)-23.34M
Levered Free Cash Flow (ttm)-10.28M